Volume 68, Issue 3, Pages (September 2015)

Slides:

Advertisements

Similar presentations

Volume 42, Issue 1, Pages 7-11 (July 2002)

Advertisements

Volume 50, Issue 3, Pages (September 2006)

Volume 45, Issue 5, Pages (May 2004)

Medical Management for BPH: The Role of Combination Therapy

Assessment and management of male lower urinary tract symptoms (LUTS)

Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): More Than Treating Symptoms? Mark J. Speakman European Urology Supplements

Volume 72, Issue 1, Pages (January 2017)

Volume 43, Issue 5, Pages (May 2003)

Volume 51, Issue 2, Pages (February 2007)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 68, Issue 6, Pages e129-e131 (December 2015)

Systematic Review of the Efficacy and Safety of High-Intensity Focussed Ultrasound for the Primary and Salvage Treatment of Prostate Cancer Marisa Warmuth,

Volume 54, Issue 6, Pages (December 2008)

Volume 60, Issue 1, Pages (July 2011)

Combination of Alfuzosin and Sildenafil is Superior to Monotherapy in Treating Lower Urinary Tract Symptoms and Erectile Dysfunction Steven A. Kaplan,

The Correlation Between Metabolic Syndrome and Prostatic Diseases

Assessment and management of male lower urinary tract symptoms (LUTS)

Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): More Than Treating Symptoms? Mark J. Speakman European Urology Supplements

Prostate Cancer Epidemic in Sight?

Volume 64, Issue 3, Pages (September 2013)

Volume 43, Issue 5, Pages (May 2003)

The Long-Term Outcome of Medical Therapy for BPH

Tumour Grade, Treatment, and Relative Survival in a Population-based Cohort of Men with Potentially Curable Prostate Cancer Sam Ladjevardi, Gabriel Sandblom,

Volume 63, Issue 1, Pages (January 2013)

Back to the Future: Introduction and Conclusions

Sexual Dysfunction and Lower Urinary Tract Symptoms (LUTS) Associated with Benign Prostatic Hyperplasia (BPH) Raymond C. Rosen, Francois Giuliano, Culley.

Evaluation and Medical Management of Benign Prostatic Hyperplasia

Volume 52, Issue 3, Pages (September 2007)

Volume 62, Issue 6, Pages (December 2012)

Volume 51, Issue 3, Pages (March 2007)

Ute Ganswindt, Arnulf Stenzl, Michael Bamberg, Claus Belka

Volume 54, Issue 5, Pages (November 2008)

Volume 60, Issue 1, Pages (July 2011)

Volume 58, Issue 3, Pages (September 2010)

Volume 60, Issue 4, Pages (October 2011)

Treatment of Symptomatic Benign Prostatic Hyperplasia: Current and Future Clinical Practice in Europe – What is Really Happening? Bob Djavan European.

Volume 61, Issue 3, Pages (March 2012)

Prostate Cancer Epidemic in Sight?

Volume 64, Issue 2, Pages (August 2013)

Volume 71, Issue 4, Pages (April 2017)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 53, Issue 6, Pages (June 2008)

Richard C. Harkaway European Urology Supplements

Karl-Dietrich Sievert, Bastian Amend, Arnulf Stenzl European Urology

Volume 50, Issue 3, Pages (September 2006)

Volume 50, Issue 5, Pages (November 2006)

Volume 46, Issue 5, Pages (November 2004)

CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System

Tim Schneider European Urology Supplements

Insights into the Relationships between Prostatic Disorders and Their Potential Impact on Future Urologic Practice Claus Roehrborn European Urology.

Volume 53, Issue 1, Pages (January 2008)

Volume 54, Issue 6, Pages (December 2008)

The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.

When to Treat the Prostate, the Bladder, or Both?

Volume 53, Issue 6, Pages (June 2008)

What are the Data on 5α-Reductase Inhibitor Treatment of Benign Prostatic Hyperplasia from Everyday Practice? François Desgrandchamps European Urology.

European Urology is “Your” Journal

Volume 75, Issue 1, Pages (January 2019)

Martin Michel, Jean de la Rosette European Urology Supplements

How Do New Data from Clinical Trials Allow Us to Optimise the Assessment and Treatment of Patients with Benign Prostatic Hyperplasia? Vincenzo Mirone

The Benefits of Dual Inhibition of 5α Reductase

Volume 53, Issue 6, Pages (June 2008)

Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma Jan Roigas European Urology Supplements Volume.

Volume 51, Issue 2, Pages (February 2007)

Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): More Than Treating Symptoms? Mark J. Speakman European Urology Supplements

Integrating Patient Risk Profiles in the Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH) in Clinical Practice

Ian W. Mills, Anna Crossland, Anup Patel, Henrikas Ramonas

Volume 54, Issue 1, Pages (July 2008)

Volume 51, Issue 5, Pages (May 2007)

Michael Marberger European Urology Supplements

Presentation transcript:

Volume 68, Issue 3, Pages 418-425 (September 2015) Drug Adherence and Clinical Outcomes for Patients Under Pharmacological Therapy for Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia: Population- based Cohort Study Luca Cindolo, Luisella Pirozzi, Caterina Fanizza, Marilena Romero, Andrea Tubaro, Riccardo Autorino, Cosimo De Nunzio, Luigi Schips European Urology Volume 68, Issue 3, Pages 418-425 (September 2015) DOI: 10.1016/j.eururo.2014.11.006 Copyright © 2014 European Association of Urology Terms and Conditions

Fig. 1 Flow chart for study inclusion for the index period January 1, 2004 to December 31, 2006. AB=alpha blocker monotherapy; CT=combination therapy; 5ARI=5-alpha reductase inhibitor monotherapy. European Urology 2015 68, 418-425DOI: (10.1016/j.eururo.2014.11.006) Copyright © 2014 European Association of Urology Terms and Conditions

Fig. 2 Drug adherence during the study period (A) in the first year of treatment and (B) during the follow-up period (2–8 yr of treatment). AB=alpha blocker monotherapy; CT=combination therapy; 5ARI=5-alpha reductase inhibitor therapy. European Urology 2015 68, 418-425DOI: (10.1016/j.eururo.2014.11.006) Copyright © 2014 European Association of Urology Terms and Conditions

Fig. 3 Event-free survival according to pharmacological therapy. (A) Hospitalization for BPH (A) and BPH surgery (B). AB=alpha blocker monotherapy; CT=combination therapy; 5ARI=5-alpha reductase inhibitor therapy. European Urology 2015 68, 418-425DOI: (10.1016/j.eururo.2014.11.006) Copyright © 2014 European Association of Urology Terms and Conditions